The anti-suicidal potential of buprenorphine: A case report

International Journal of Psychiatry in Medicine

Volumn 47, Issue 2, 2014, Pages 169-174

  Striebel, Joan M ^a,b   Kalapatapu, Raj K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

buprenorphine; depression; pain; suicidality

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DIAMORPHINE; METHADONE; NEUROPEPTIDE; NEUROTRANSMITTER; OPIATE; OXYCODONE;

ADULT; ANALGESIA; ARTICLE; BACKACHE; BEREAVEMENT; CASE REPORT; CHRONIC PAIN; COMORBIDITY; DEPRESSION; DRUG EFFECT; DSM-5; FEMALE; FOLLOW UP; HUMAN; MAJOR DEPRESSION; OPIOID FACILITATED ANALGESIA; PAIN; PATIENT REFERRAL; PHARMACODYNAMICS; PRESCRIPTION; RISK ASSESSMENT; SUBSTANCE ABUSE; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; TREATMENT RESISTANT DEPRESSION; UNEMPLOYMENT; WITHDRAWAL SYNDROME;

BUPRENORPHINE; DEPRESSION; PAIN; SUICIDALITY;

ADMINISTRATION, SUBLINGUAL; ALLOSTERIC REGULATION; ANALGESICS, OPIOID; BRAIN; BUPRENORPHINE; CHRONIC PAIN; COMORBIDITY; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG INTERACTIONS; FEMALE; HUMANS; MIDDLE AGED; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; SUBSTANCE ABUSE TREATMENT CENTERS; SUICIDAL IDEATION; SUICIDE; SUICIDE, ATTEMPTED;

EID: 84901757022     PISSN: 00912174     EISSN: 15413527     Source Type: Journal    
DOI: 10.2190/PM.47.2.g     Document Type: Article

References (16)

1. Yoshimasu K, Kiyohara C, Miyashita K. Suicidal risk factors and completed suicide: Meta-analyses based on psychological autopsy studies. Environmental Health and Preventive Medicine 2008;13:243-256.
2. Ilgen MA, Kleinberg F, Ignacio RV, Bohnert AS, Valenstein M, McCarthy JF, Blow FC, Katz IR. Noncancer pain conditions and risk of suicide. Journal of the American Medical Association: Psychiatry 2013;70:692-697.
3. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010; 35:217-238.
4. Elman I, Borsook D, Volkow ND. Pain and suicidality: Insights from reward and addiction neuroscience. Progress in Neurobiology 2013;109:1-27.
5. Egli M, Koob GF, Edwards S. Alcohol dependence as a chronic pain disorder. Neuroscience and Biobehavioral Reviews 2012;36:2179-2192.
6. Garland EL, Froeliger B, Zeidan F, Suveg K, Howard MO. The downward spiral of chronic pain, prescription opioid misuse, and addiction: Cognitive, affective, and neuropsychopharmacologic pathways. Neuroscience and Biobehavioral Reviews 2013 [Epub ahead of print].
7. Chandley MJ, Ordway GA. Noradrenergic Dysfunction in Depression and Suicide. In Y. Dwivedi, editor. The neurobiological basis of suicide. Boca Raton, FL: CRC Press, 2012: Chapter 3.
8. Serafini G, Pompili M, Lindqvist D, Dwivedi Y, Girardi P. The role of neuropeptides in suicidal behavior: A systematic review. BioMed Research International 2013; 2013:687575.
9. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Archives of General Psychiatry 1997;54:597-606. (Pubitemid 27306570)
10. Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. The Journal of Neuroscience 2008;28:407-414.
11. Van't Veer A, Carlezon WA, Jr. Role of kappa-opioid receptors in stress and anxietyrelated behavior. Psychopharmacology 2013;229:435-452.
12. Knoll AT, Carlezon WA. Dynorphin, stress, and depression. Brain Research 2010; 1314c:56.
13. Koob GF, Zorrilla EP. Neurobiological mechanisms of addiction: Focus on corticotropinreleasing factor. Current Opinion in Investigational Drugs 2010;11:63-71.
14. Shirayama Y, Ishida H, Iwata M, Hazama GI, Kawahara R, Duman RS. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. Journal of Neurochemistry 2004; 90:1258-1268. (Pubitemid 39167359)
15. Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. Journal of Clinical Psychopharmacology 1995;15:49-57.
16. Emrich HM, Vogt P, Herz A, Kissling W. Antidepressant effects of buprenorphine. Lancet 1982;2:709. (Pubitemid 12061536)